Finance

Lists
Why is GPCR down 7.15%?
Dive Deeper
GPCR:NASDAQ
Structure Therapeutics Inc
$18.57
-7.15%
(-1.43) 1D
$18.60
+0.16% (+0.030)
Pre-market
Closed: Nov 16, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GPCR...
Open
$19.82
High
$19.99
Low
$18.38
Mkt. cap
1.33B
Avg. vol.
1.12M
Volume
7.74K
52-wk high
$94.90
52-wk low
$18.38
EPS
-$3.98
Beta
-1.20
Shares outstanding
71.59M
No. of employees
281
Open
$19.82
High
$19.99
Low
$18.38
Mkt. cap
1.33B
Avg. vol.
1.12M
Volume
7.74K
52-wk high
$94.90
52-wk low
$18.38
EPS
-$3.98
Beta
-1.20
Shares outstanding
71.59M
No. of employees
281
News stories
From web sources and news partners
About Structure Therapeutics Inc
CEO-
Employees281
Founded2016
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 10 analysts giving stock ratings to GPCR in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for GPCR in the last 3 months.
Highest
Current $18.57
$145.00 (+680.83%)
Average
$105.56 (+468.44%)
Lowest
$70.00 (+276.95%)
Analyst
Recommendation
Action
Price target
Projected
Date
Terence Flynn
Morgan Stanley
Buy
Maintained
$117.00
+530%
11/13/2026
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
$70.00
+277%
11/12/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
$90.00
+384.7%
11/10/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$93.00
+400.8%
11/10/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
$107.00
+476.2%
11/10/2026
Evan Seigerman
BMO Capital
Buy
Reiterated
$145.00
+680.8%
11/10/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
$104.00
+460%
09/08/2026
Roger Song
Jefferies
Buy
Maintained
$125.00
+573.1%
09/08/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
09/08/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$99.00
+433.1%
09/08/2026
Hardik Parikh
J.P. Morgan
Buy
Maintained
$100.00
+438.5%
08/17/2026
Samantha Semenkow
Citi
Buy
Maintained
$97.00
+422.3%
08/10/2026
Unknown Analyst
Jefferies
Buy
Maintained
$125.00
+573.1%
08/07/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$110.00
+492.4%
08/07/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$140.00
+653.9%
08/07/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Maintained
$101.00
+443.9%
06/07/2026
Seamus Fernandez
Guggenheim
Buy
Maintained
$140.00
+653.9%
05/07/2026
Corinne Johnson
Goldman Sachs
Buy
Maintained
$101.00
+443.9%
03/16/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
68.69M
66.51M
100.06M
134.55M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.57M
22.87M
18.57M
21.78M
Operating expense
-13.74M
89.38M
118.63M
156.33M
Total operating expenses
-13.74M
89.38M
118.63M
156.33M
Operating income
13.74M
-89.38M
-118.63M
-156.33M
Other non operating income
-
-
-
-
EBT including unusual items
33.17M
-75.78M
-105.92M
-144.59M
EBT excluding unusual items
35.75M
-75.78M
-105.92M
-144.59M
Income tax expense
170.00K
190.00K
234.00K
171.00K
Effective tax rate
0.51%
-0.25%
-0.22%
-0.12%
Other operating expenses
-100.00M
-
-
-
Net income
33.00M
-75.97M
-106.16M
-144.76M
Net profit margin
-
-
-
-
Earnings per share
-0.46
-0.35
-0.49
-0.66
Interest and investment income
22.01M
13.60M
12.70M
11.75M
Interest expense
-
-
-
-
Net interest expenses
22.01M
13.60M
12.70M
11.75M
Depreciation and amortization charges
-
-
-
-
EBITDA
14.47M
-88.79M
-118.06M
-156.31M
Gain or loss from assets sale
-10.25M
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps